Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Atadja

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Biological Chemistry|December 12, 2001
Isolation and characterization of a novel class II histone deacetylase, HDAC10Denise D Fischer, Richard Cai, Umesh Bhatia, et al.
The Journal of Biological Chemistry|September 2, 2011
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylationLi Wang, Ling Li, Hailong Zhang, et al.
International Journal of Cancer|August 18, 2010
Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostatBen P Martin, Ailsa J Frew, Michael Bots, et al.
Cancer Research|August 28, 2003
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cellsRamadevi Nimmanapalli, Lianne Fuino, Purva Bali, et al.
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Biochemical Pharmacology|June 9, 2004
In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitorsAngela Brieger, Simone Boehrer, Simone Schaaf, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
The Journal of Biological Chemistry|January 13, 2010
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayRoberto R Rosato, Sarah S Kolla, Stefanie K Hock, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Blood|May 27, 2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsLaurence Catley, Ellen Weisberg, Tanyel Kiziltepe, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Biological Chemistry|December 12, 2001
Isolation and characterization of a novel class II histone deacetylase, HDAC10Denise D Fischer, Richard Cai, Umesh Bhatia, et al.
The Journal of Biological Chemistry|September 2, 2011
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylationLi Wang, Ling Li, Hailong Zhang, et al.
International Journal of Cancer|August 18, 2010
Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostatBen P Martin, Ailsa J Frew, Michael Bots, et al.
Cancer Research|August 28, 2003
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cellsRamadevi Nimmanapalli, Lianne Fuino, Purva Bali, et al.
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Biochemical Pharmacology|June 9, 2004
In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitorsAngela Brieger, Simone Boehrer, Simone Schaaf, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
The Journal of Biological Chemistry|January 13, 2010
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayRoberto R Rosato, Sarah S Kolla, Stefanie K Hock, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Blood|May 27, 2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsLaurence Catley, Ellen Weisberg, Tanyel Kiziltepe, et al.
Pageof 11